Pierre Sayad
Net worth: 208 679 $ as of 31/05/2026
Net worth: 208 679 $ as of 31/05/2026
Pierre S.
Sayad is currently Chief Medical Officer at Fennec Pharmaceuticals, Inc. since 2024.
Formerly, Dr. Sayad was Senior Vice President-Global Medical Affairs at International Myeloma Foundation, Vice President-Global Medical & Scientific Affairs at Karyopharm Therapeutics, Inc., and Chief Operating & Medical Officer at Zephyr Group, Inc. Education includes graduate studies at Loma Linda University and undergraduate studies at San Jose State University.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 01/06/2026 | 21,015 ( 0.06% ) | 208 679 $ | 31/05/2026 |
| Companies | Position | Start |
|---|---|---|
| FENNEC PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 28/10/2024 |
| Companies | Position | End |
|---|---|---|
International Myeloma Foundation
International Myeloma Foundation Miscellaneous Commercial ServicesCommercial Services Supports myeloma patients | Corporate Officer/Principal | - |
| KARYOPHARM THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Fennec Pharmaceuticals, Inc.
Fennec Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and commercializes therapeutic products which dedicated to improving the lives of children with cancer who experience hearing loss | Health Technology |
International Myeloma Foundation
International Myeloma Foundation Miscellaneous Commercial ServicesCommercial Services Supports myeloma patients | Commercial Services |
Loma Linda University
Loma Linda University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
San Jose State University
San Jose State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Select your edition
All financial news and data tailored to specific country editions